

Supplementary Table 1. Clinical characteristics of patients.

Group	Pt #	Age Sex	Underlying Disease	HCT-CI	Disease Risk*	Conditioning Regimen	Conditioning Intensity	HCT Source	HCT manipulation
Fungal BSI	1	54 F	Multiple Myeloma	5	High	bu/mel/flu	MA	Unrelated Non-identical	TCD
	2	56 F	Myelodysplastic Syndrome	4	Low	flu/cy/thio/TBI-400	RIC	Double Cord	unmodified
	3	52 F	Angioimmunoblastic T-Cell Lymphoma	3	Low	flu/mel	RIC	Unrelated Identical	unmodified
	4	49 F	Diffuse, large cell Lymphoma	4	Intermediate	flu/mel	RIC	Unrelated Identical	unmodified
	5	73 F	Acute Myelogenous Leukemia	7	Low	mel/thio/flu	MA	Related Haploidentical	unmodified
	6	65 M	Acute Myelogenous Leukemia	5	Low	flu/cy/thio/TBI-400	RIC	Double Cord + Haploidentical	TCD
	7	68 F	Multiple Myeloma	0	High	bu/mel/flu	MA	Unrelated Non-identical	TCD
	8	24 F	Aplastic Anemia	1	N/A	flu/cy/TBI-200	NMA	Unrelated Identical	unmodified
Control	9	39 M	Acute Myelogenous Leukemia	0	Intermediate	bu/mel/flu	MA	Unrelated Identical	TCD
	10	62 M	Myelodysplastic Syndrome	2	High	bu/flu/mel	MA	Related Identical Sibling	TCD
	11	72 M	Myelodysplastic Syndrome	4	High	flu/mel	RIC	Unrelated Identical	unmodified
	12	69 M	Mantle cell Lymphoma	2	Intermediate	cy/flu/TBI-200	NMA	Related Identical Sibling	unmodified
	13	68 F	Myelodysplastic Syndrome	1	N/A	mel/thio/flu	MA	Haploidentical	unmodified
	14	72 M	Myelodysplastic Syndrome	0	High	flu/mel	RIC	Unrelated Non-identical	unmodified
	15	69 M	Chronic T-Prolymphocytic Leukemia	11	Intermediate	flu/mel	RIC	Unrelated Identical	unmodified

\* Disease risk based on the ASBMT Request for Information Disease Classifications schema.

HCT, hematopoietic cell transplantation; BSI, bloodstream infection; HCT-CI: HCT-specific comorbidity index; flu, fludarabine; cy, cyclophosphamide; mel, melphalan; bu, busulfan; thio, thiotepa; MA, myeloablative; RIC, reduced intensity; NMA, nonmyeloablative; TCD, T-cell depleted (ex-vivo); N/A: not available.